Replies to post #54240 on Innovation Pharmaceuticals Inc (IPIX)

[I Need Help]

RJFL, don't disagree with your comments. I can relate.

I read your post, and I think you made an excellent case for why the share price has not performed as well as many have prognosticated. You make a good case for why investors, institutions, and partners may have second thoughts.

Lots of ways to travel. Though the investor-passengers pay for the train, its really Menon's and Ehrlich's locomotive to take passengers where they will. The ticket to ride is worth whatever Menon and Ehrlich determine it to be worth. The destination wherever Menon and Ehrlich decide. Passengers are happily riding in the caboose, watching the pretty scenery, reading the brochures provided, with full faith in Menon and Ehrlich, destination unknown.

The problem for CTIX is comparative alternatives. Lots of pretty trains, planes, and automobiles. Filtered through your lenses, CTIX is the way to ride. From Brenum's last post (54234), looks like he's taking a different mode of transport for the time being. The market speaks. What was the last price?

Same information, you see things one way, Brenum another, and me another yet. The market speaks. What was the last price?

[steelyeye]

Nice response and I agree with this:

... I think the delayed approach Ehrlich has taken with regards to adding independent board members makes very good sense from a fiscal standpoint. Even if we had all the board members in place right now if I understand the NYSE and NASDAQ requirements we could not uplist at this time due to share price (and perhaps other factors), thus paying for the board members at this time is premature. That said, I also think Leo probably has already had several interviews with potential board members and it may very well be a case of as soon as we meet the other criteria we will sign the candidates and then make the application for uplisting at the same time. In this manner the costs for the board are delayed until the other criteria for uplisting are met, makes good sense to me

to me, the hidden question from the poster you responded to, is whether an independent board is necessary first to obtain a partnership with big pharma? (the chicken/egg dilemma).

I would put the dilemma a bit differently: without an independent board of directors, what will Leo and Krishna have to "give up" in order to get a decent partnership at all? A board seat? Future Royalties %? Plus?

For myself, 3 more people right now making decisions with the power to overrule the current two insiders, doesn't make sense. But later this year it most definitely will make sense because the landscape will be larger and the decisions greater. So I hope you are right that Leo has people interviewed and vetted for when the time is right. Again, with Leo and Menon holding the majority of shares, there are pluses and minuses.

I don't see a candy store but I don't see the kind of delayed gratification that would align better with what shareholders have been doing.